Michael OLLMANN
7Patents
2h-index
19Co-inventors
48Inventor score
Filing activity: Oct 12, 2001 → Oct 26, 2020
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US6515109B1 | Human ECT2 polypeptide | Chemistry; Metallurgy | 10 | Expired |
| US6630297B2 | Methods of screening for agents that modulate the interaction of human ECT2 polypeptide with an ECT2 binding target | Chemistry; Metallurgy | 3 | Expired |
| US8288119B2 | PGDS as modifiers of the PTEN pathway and methods of use | Emerging Cross-Sectional Technologies | 0 | Active |
| US7927872B2 | ALDOs as modifiers of the IGF pathway and methods of use | Emerging Cross-Sectional Technologies | 0 | Active |
| US11732266B2 | RNAi constructs for inhibiting ASGR1 expression and methods of use thereof | Chemistry; Metallurgy | 0 | Active |
| US10870856B2 | RNAi constructs for inhibiting ASGR1 expression and methods of use thereof | Chemistry; Metallurgy | 0 | Active |
| US8758994B2 | CDK9 as modifier of the IGF pathway and methods of use | Emerging Cross-Sectional Technologies | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.